A recent report showed that levels of proteolytic fragment of PTHrP are elevated in the plasma of breast cancer patients with bone metastasis vs. non-bone metastatic tumors, and could be utilized as a biomarker for bone-metastasized breast cancer (Washam et al., 2013). Here, PTHLH is linked to bone metastasis.